India reported 2,58,089 fresh Covid-19 cases, 4% lower than the previous day figure. 1,51,740 patients recovered during the last 24 hours. And with this the recovery rate reaches at 94.27%. The daily positivity rate reaches at 19.65%.
India’s active caseload currently stands 16,56,341, active cases stand at 4.43%. The number of Covid-19 cases has started falling in a few cities in India, but it is still unclear whether the country is under-reporting the cases or if there has been a fall in testing.
Relatively, three states namely Punjab ( 7,396), Gujarat (10,150) and West Bengal (14,938) reported maximum Covid-19 fresh cases in the last 24 hours.
According to the data given by Health Ministry, a total of 8,209 Omicron cases were reported in India so far.
Three states namely Maharashtra (41,327), Kerala (18,123) and Delhi (18,286) recorded more than 18,000 fresh Covid-19 cases in the last 24 hours.
Commenting on the considerable fall in Covid-19 cases, Delhi Health Minister Satyendar Jain has said that less testing does not mean fewer Covid-19 cases claiming that whether its mild, asymptomatic, or high-risk contact cases, everyone is getting tested. Jain assured that the state is conducting 3 times more tests than required by the ICMR guidelines.
In a bid to ramp up the vaccination process, the country has administered the cumulative figure of 157.20 crore vaccine doses so far.
According to a preliminary analysis by IIT Madras, India’s R-value was close to 2.9 nationally from December 25 to December 31 while it was 4 between January 1 and 6. It reported another drop at 2.2 between January 7 and January 13. The R value marks the number of people an infected person can spread the disease to. A pandemic is considered to end if this value goes below 1.
India could soon have its first messenger or mRNA vaccine, with the near completion of Phase 3 clinical trials by Gennova Biopharmaceuticals. Media reports say that the Pune-based Gennova company has developed the mRNA vaccine for the Omicron variant in the laboratory, which will be tested for human use for efficacy and immunogenicity soon.